Updated Jul 16, 2026
WALDRON RICHARD A is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days.
Richard A. Waldron is the Chief Financial Officer of BioAtla, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumors. He has filed multiple SEC documents related to his role, indicating active involvement in the company's financial operations.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-02 | BCAB | BioAtla, Inc. | F — Tax withholding / forfeiture | 2.7K | $0.25 | $674 |
| 2025-12-01 | BCAB | BioAtla, Inc. | F — Tax withholding / forfeiture | 2.4K | $0.90 | $2K |
| 2025-08-31 | BCAB | BioAtla, Inc. | F — Tax withholding / forfeiture | 2.4K | $0.46 | $1K |
| 2025-05-31 | BCAB | BioAtla, Inc. | F — Tax withholding / forfeiture | 2.4K | $0.41 | $970 |
Richard A. Waldron is the Chief Financial Officer of BioAtla, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumors. He has filed multiple SEC documents related to his role, indicating active involvement in the company's financial operations.…
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live WALDRON RICHARD A profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.